Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma

Japanese Journal of Clinical Oncology · Published 2026-02-17 · DOI 10.1093/jjco/hyag037

Authors being retrieved — see the publisher record. https://doi.org/10.1093/jjco/hyag037

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Real-World Effectiveness and Tolerability of Belzutifan in Sporadic Clear Cell Renal Cell Carcinoma: A Retrospective Cohort Study With Exploratory Genomic Correlation · Clinical Genitourinary Cancer · 2026 · Cites or is cited by this article
End-of-life cancer care quality in rural areas of Japan: an exploratory bereaved family survey · Japanese Journal of Clinical Oncology · 2026 · Same journal
Developing quality indicators for supportive care in cancer treatment: a modified Delphi method · Japanese Journal of Clinical Oncology · 2026 · Same journal
Hereditary cancer multigene panel testing in the United States and Europe: real-world constraints and implications for responsible integration in Japan · Japanese Journal of Clinical Oncology · 2026 · Same journal
A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART) · Japanese Journal of Clinical Oncology · 2026 · Same journal
Resolution of peritoneal metastases in CLDN18.2-positive gastric cancer treated with CAPOX plus zolbetuximab · Japanese Journal of Clinical Oncology · 2026 · Same journal
Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study · Japanese Journal of Clinical Oncology · 2026 · Same journal
Reconsidering prostate cancer screening: limitations of net survival and the primacy of overall survival as an endpoint · Japanese Journal of Clinical Oncology · 2026 · Same journal
A multicenter randomized phase III trial of weekly cisplatin chemoradiotherapy versus radiotherapy in elderly patients with head and neck squamous cell carcinoma unfit for high-dose cisplatin: JCOG2405 (ELDER-WEEKLY) · Japanese Journal of Clinical Oncology · 2026 · Same journal
Age-standardized mortality-to-incidence ratio for lymphoma in the world · Japanese Journal of Clinical Oncology · 2026 · Same journal